Alpine Immune Sciences Inc (NASDAQ:ALPN)

8.27
Delayed Data
As of 4:00pm ET
 +0.02 / +0.24%
Today’s Change
6.00
Today|||52-Week Range
14.40
-40.29%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$250.2M

Company Description

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Contact Information

Alpine Immune Sciences, Inc.
188 East Blaine Street
Seattle Washington 98102
P:(206) 788-4545
Investor Relations:

Employees

Shareholders

Mutual fund holders6.22%
Individual stakeholders45.75%
Other institutional26.19%

Top Executives

Mitchell H. GoldExecutive Chairman & Chief Executive Officer
Stanford L. PengPresident & Head-Research & Development
Thaedra ThullberryFinance Director
James Paul RickeyChief Financial Officer, Secretary & Senior VP
Wayne R. GombotzChief Technology Officer